These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4093207)

  • 1. Pharmacokinetics and bioavailability of isosorbide-5-mononitrate in humans.
    Rameis H; Bacher S; Eichler HG; Horwatitsch H
    Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):678-80. PubMed ID: 4093207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
    Geigenberger A; Degen J; Maier-Lenz H
    Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
    Rietbrock N; Knoll J; Merz PG; Menke G
    Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
    Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer aspects of the pharmacokinetics of organic nitrates.
    Chasseaud LF
    Z Kardiol; 1983; 72 Suppl 3():20-3. PubMed ID: 6666223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard).
    Neugebauer G; Akpan W; Stemmle B; Jaeger H; Mosberg H; Lutz D
    Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):34-8. PubMed ID: 2744904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate].
    Heidemann R; Gracien E; Menke G; Rietbrock N
    Dtsch Med Wochenschr; 1987 May; 112(18):719-22. PubMed ID: 3569063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isosorbide 5-mononitrate pharmacokinetics in humans.
    Taylor T; Chasseaud LF; Major R; Doyle E; Darragh A
    Biopharm Drug Dispos; 1981; 2(3):255-63. PubMed ID: 7295882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.
    Thomson AH; Miller SH; Green ST; Whiting B
    Eur J Clin Pharmacol; 1988; 34(1):47-50. PubMed ID: 3360048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
    Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF
    Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
    Muck B; Bonn R; Rietbrock N
    Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers.
    Storm G; Oosterhuis B; Bron J; Wittebrood AJ; De Jong AP; Jonkman JH
    Biopharm Drug Dispos; 1991 Dec; 12(9):661-72. PubMed ID: 1790311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics and bioavailability of a new slow-release isosorbide-5-mononitrate system].
    Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
    Cardiologia; 1987 Nov; 32(11):1287-91. PubMed ID: 3447701
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
    Thadani U
    Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isosorbide 5-mononitrate pharmacokinetics.
    Chasseaud LF
    Cardiology; 1987; 74 Suppl 1():6-11. PubMed ID: 3300979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
    Parker JO
    Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
    Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
    Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.